Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Regulus reports preliminary interim data from mouse chronic toxicity study of RGLS-4326

Jan. 7, 2019

FDA accepts IND for phase Ib study of DM-199 for diabetes-related CKD

Jan. 3, 2019

Failure of AMPK caused by multiple uremic factors is a key mechanism of energy depletion in CKD

Jan. 3, 2019

Perlara and Rambam Medical Center enter APOL1 kidney disease partnership

Dec. 28, 2018

First patient dosed in pivotal phase III PROTECT study of sparsentan

Dec. 28, 2018

Antiviral response damages kidney in bacterial sepsis

Dec. 14, 2018

New phase IIb trial investigates efficacy of male contraceptive gel

Nov. 29, 2018

Dimerix begins dosing in phase II trials of DMX-200 for kidney disease

Nov. 23, 2018

Nash Pharmaceuticals reports data on NP-135 in mouse model of kidney fibrosis

Nov. 20, 2018

Calliditas begins phase III study of Nefecon in IgA nephropathy

Nov. 14, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...